Drug Profile
Research programme: metalloproteinase inhibitors - OSI/Vernalis
Alternative Names: Matrix metalloproteinase inhibitors research programme - OSI/Vernalis; Metalloprotease inhibitors research programme - OSI/Vernalis; Metalloproteinase inhibitors research programme - OSI/Vernalis; MMP inhibitors research programme - OSI/Vernalis; Research programme: matrix metalloproteinase inhibitors - OSI/Vernalis; Research programme: metalloprotease inhibitors - OSI/Vernalis; Research programme: MMP inhibitors - OSI/VernalisLatest Information Update: 09 Apr 2021
Price :
$50
*
At a glance
- Originator OSI Pharmaceuticals; Vernalis
- Class
- Mechanism of Action Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bacterial infections; Inflammation; Rheumatic disorders
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 14 Jan 2005 Discontinued - Preclinical for Bacterial infections in United Kingdom (unspecified route)
- 14 Jan 2005 Discontinued - Preclinical for Inflammation in United Kingdom (unspecified route)